1 9 1 a r t I C l e S ASDs are associated with a wide range of cognitive and behavioral abnormalities 1,2 . It is estimated that many hundreds of genes may contribute to autism and related phenotypes 2, 3 . Functionally important de novo mutations associated with ASDs are individually rare, but their collective contribution to sporadic ASD cases is likely to be substantial as a result of a large number of target genes [3] [4] [5] [6] [7] [8] [9] [10] . Several recent studies have identified a large collection of de novo mutations associated with ASDs, including copy number variations (CNVs) 6 and single nucleotide variations (SNVs) 3, 7, 8, 11 . These studies demonstrated that truncating SNVs (such as nonsense, splice site and frameshift mutations) and large CNVs are likely to have a causal role in ASDs.
a r t I C l e S ASDs are associated with a wide range of cognitive and behavioral abnormalities 1,2 . It is estimated that many hundreds of genes may contribute to autism and related phenotypes 2, 3 . Functionally important de novo mutations associated with ASDs are individually rare, but their collective contribution to sporadic ASD cases is likely to be substantial as a result of a large number of target genes [3] [4] [5] [6] [7] [8] [9] [10] . Several recent studies have identified a large collection of de novo mutations associated with ASDs, including copy number variations (CNVs) 6 and single nucleotide variations (SNVs) 3, 7, 8, 11 . These studies demonstrated that truncating SNVs (such as nonsense, splice site and frameshift mutations) and large CNVs are likely to have a causal role in ASDs.
To explore the underlying biological pathways, we previously developed a computational approach (NETBAG+) that searches for cohesive biological networks using a diverse collection of diseaseassociated genetic variants 12, 13 . Using network-based approaches, we and others recently found that genetic variations associated with ASDs and other psychiatric disorders converge on several biological networks that are involved in neurogenesis and synaptic function [12] [13] [14] [15] . In parallel with the identification of disease-associated genetic variations, complementary data sets of brain-related functional and phenotypic resources are rapidly being accumulated. These include a comprehensive database of gene expression across different cell types, distinct anatomical brain regions and developmental stages 16, 17 . In addition, resources such as the Simons Simplex Collection (SSC) 18 have assembled a large compendium of ASD-related phenotypic data, including intelligence and social phenotypic scores. We focused our analyses on a set of genes that were implicated by our network-based computational approach and on all de novo truncating mutations from several recent studies. These two independent approaches provided us with complementary genes sets enriched in causal ASD mutations.
We investigated the temporal, spatial and cell-specific expression profiles of implicated genes. We also explored how expression and functional properties of autism-associated genes affect ASD phenotypes.
RESULTS

Functional gene networks affected by de novo mutations
To elucidate functional networks perturbed in ASD, we applied NETBAG+ to a set of genes affected by de novo CNVs and SNVs observed in autistic patients from the SSC 3, [6] [7] [8] . All of the mutations used as the input for our analyses were obtained using genomewide methodologies and therefore are not biased by any preexisting hypotheses of ASD etiology. The combined input data contained a total of 991 unique genes from 624 independent genomic loci, including 580 unique genes with de novo SNVs and 434 genes within de novo CNVs (Supplementary Table 1) ; we note that the number of genomic loci used was considerably larger than the 47 loci considered in our previous analysis of de novo CNV events in autism 13 . We used NETBAG+ to identify a subset of the input genes that are strongly connected in the underlying phenotypic network (Online Methods). The NETBAG+ search revealed a functional network containing 159 genes (P = 0.036; Fig. 1 and Supplementary Table 2), of which 131 genes were affected by de novo SNVs and 31 by de novo CNVs. The network's significance was estimated using random input sets that matched the real data in terms of protein length and network connectivity. Notably, no significant networks were detected using genes associated with the 368 non-synonymous de novo mutations identified in siblings.
To explore the biological functions associated with the implicated network, we used DAVID 19 to identify Gene Ontology (GO) terms that were significantly enriched among network gene a r t I C l e S annotations ( Table 1) . This analysis identified a diverse set of functions associated with the implicated network, including synaptic function, chromatin modification and calcium channel activity. To better understand the functional relationships between genes in the network, we performed hierarchical clustering of the network genes using the strength of interactions in the phenotypic network as a metric (Supplementary Fig. 1 ). This analysis identified four major network clusters, each associated with distinct and non-overlapping biological functions (Supplementary Table 3) .
One cluster in our network ( Fig. 1) contained genes responsible for synapse formation and function. This cluster contained neurexin (NRXN) and neuroligin (NRLG), as well as important components (SHANK2 and DLG2/DLG4) of the postsynaptic density (PSD) of excitatory synapses. A related cluster included a diverse set of ion channels and receptors. This cluster contained genes (CACNA1B, CACNA1D, CACNA1E, CACNA1S) for subunits of several voltagedependent calcium channels, which are important in learning and memory 20 . The largest cluster of the implicated network contained genes that are associated with neuronal signaling and migration (NF1, DCC, EPHA1/B2), intracellular signaling (MAPK3, EGFR, PTEN, MDM2, CTNNB1, PRKCA, LIMK1), and the development of neuronal projections and actin cytoskeleton (CYFIP1, TRIO, SPTAN1, FLNA, ACTN4). As we have previously demonstrated, ASD-associated mutations often perturb multiple signaling pathways that converge on the regulation of actin cytoskeleton and other structural processes that are required for neuron migration, cell-cell adhesion and the development of neuronal projections 12, 21, 22 . Many genes in the clusters described above encode proteins related to the growth and function of dendritic spines, which have been implicated in our previous analyses of genetic insults in ASDs and schizophrenia 12, 13 . The final cluster was primarily related to functions associated with chromatin modifications, chromatin remodeling and transcriptional regulation. Notably, there is growing evidence that chromatin regulatory mechanisms crucially affect various stages of neural development, neuroplasticity and learning 23 . This cluster also contained genes involved in other processes that have been implicated in ASDs: RNA interference (DICER1, AGO1/EIF2C1), translation (EIF4A1, EIF4G1, EIF3G) and splicing (SFPQ, TRA2B) 24 .
Association of the implicated genes with specific functional subsets In addition to the molecular and biological GO categories discussed above, we investigated whether there was an overlap between the network and specific gene subsets that may highlight the phenotypic and functional properties of the network genes. Recent exome-sequencing studies have revealed recurrent truncating mutations in several genes (ADNP, ANK2, ARID1B, CHD8, CUL3, DYRK1A, GRIN2B, RPS6KB2   RPS6KA3   NUAK1   DDR2   LRP2  LRP1  TCF7L1   PSEN1   JUP  AXIN1   SMAD2   CTNNA3   CDH5   PTPRM   PTPRK   RUVBL1   TRRAP NOLC1   CTNNB1   DLG2  RIMS1   NLGN1   IQGAP2 CACNA1S RYR1
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Figure 1
The network implicated by NETBAG+ based on ASD-associated de novo SNVs and CNVs from recent studies (network is comprised of 159 genes, P = 0.036). Node sizes are proportional to the contributions of each gene to the overall network score and edge widths are proportional to the likelihood that the corresponding gene pair contributes to the same genetic phenotype (Online Methods). For clarity, only the two strongest edges for each gene are shown. Node shapes indicate types of the corresponding mutations: circles represent genes from SNVs, squares represent genes from CNVs and diamonds represent genes affected by both mutation types. The network was divided into four cohesive functional clusters (indicated by node colors) using hierarchical clustering ( Supplementary Fig. 1 ); general biological functions of these clusters, determined using DAVID, are shown (see Supplementary  Table 3 for a complete list of GO terms associated with each cluster). Gray nodes represent genes that are not members of the network clusters. npg a r t I C l e S KATNAL2, POGZ, SCN2A and TBR1) 3, 7, 8, 11, 25 . Although only 131 of 580 (~23%) of all genes harboring missense SNVs form the implicated network, 6 of 11 genes with recurrent truncating mutations are in the network (Fisher's exact one-tail test, P = 0.02). This suggests that there is a substantial enrichment of causal genes in the implicated network. Because ASD de novo mutations are predominantly heterozygous, it is likely that true causal mutations would preferentially target haploinsufficient genes. Indeed, using haploinsufficiency probabilities from a recent study 26 , we found that genes in the implicated network were significantly more likely to be haploinsufficient than genes that were not selected by NETBAG+ (median probability for network and nonnetwork genes are 0.57 and 0.32, respectively; Wilcoxon rank-sum two-tail test, P < 10 −14 ); a similar result was also observed for genes with recurrent truncating mutations (median probability for genes with recurrent truncating mutations and unaffected sibling SNV genes are 0.69 and 0.39, respectively; Wilcoxon rank-sum two tail, P = 0.016). We also considered the Genomic Evolutionary Rate Profiling (GERP) scores to characterize the severity of SNV mutations (see Online Methods). Notably, the average GERP score of network genes was significantly higher than the average GERP score of genes not selected into the network (average network and non-network GERP scores are 4.0 and 3.3, respectively; Wilcoxon rank-sum one tail, P = 0.001). As higher GERP scores correspond to more damaging mutations, this analysis demonstrates that NETBAG predominantly selects genes harboring SNVs with potentially stronger functional effect. Notably, a recent exome study showed a significant overlap between genes harboring truncating ASD de novo SNVs and targets of the fragile X mental retardation protein (FMRP) 3, 27 . FMRP is an RNA-binding protein that is essential for a wide array of cognitive functions including synaptic plasticity and learning 28, 29 . Failure to properly express FMRP can cause fragile X syndrome, a genetic disorder resulting in a spectrum of cognitive disabilities often accompanied by autistic symptoms. Following a previous analysis 3 of truncating de novo SNVs, we calculated the expected number of FMRP targets for ASD genes by inferring gene mutabilities from a large exome-sequencing study 30 (Online Methods); the expected number of FMRP targets was then compared with the observed number in various ASD gene sets ( Table 2 ). This analysis revealed that, similar to truncating SNV genes, genes in the implicated network were significantly enriched for FMRP targets (truncating SNV gene enrichment 1:2.13, twotail binomial test, P = 3 × 10 −4 ; network gene enrichment 1:2.78, P = 3 × 10 −11 ). The enrichment remained significant when considering only network genes harboring non-truncating SNVs (enrichment = 1:2.67, P = 4 × 10 −9 ). Significant enrichment was also observed for FMRP targets from another recent study (Supplementary Table 5 ) 31 . In contrast, there was no significant enrichment for proband SNV genes that were not selected to the network (P = 0.2) nor for de novo SNV genes from unaffected siblings (P = 0.15). Furthermore, enrichment for FMRP targets remained significant when we separately considered each of the four functional clusters of the implicated network ( Table 2) . Overall, these analyses confirm that FMRP targets are important for autism etiology and suggest a causal role for a substantial fraction of genes with non-truncating de-novo SNVs.
Genes forming the PSD are also likely to be important in ASDs and other psychiatric disorders 12, 32 . The PSD is localized at the postsynaptic membrane of excitatory synapses and is crucial to synaptic communication and plasticity 25, 33, 34 . There was a significant enrichment of PSD-associated genes in the implicated network (enrichment 1:3.4, two-tail binomial test, P = 7 × 10 −9 ; Supplementary Table 5 ) and marginal enrichment for truncating de novo SNVs in probands (enrichment 1:1.9, P = 0.05). No enrichment was observed for genes harboring SNVs in unaffected siblings (enrichment 1:1.05, P = 0.8). For genes not selected to the network, PSD genes were significantly under-represented (enrichment 1:0.58, P = 0.04).
Temporal and spatial brain expression patterns of implicated genes Gene expression patterns provide important clues for understanding physiological and developmental contexts of gene function. Thus, we next investigated brain expression of the ASD-implicated genes Supplementary Table 3 . The enrichment calculations were performed using the default background set of all human genes; similar enrichment results were also obtained using brain-expressed genes as background (Supplementary Table 4 ). The expected and observed number of FMRP targets 27 among different sets of implicated genes. The expected numbers of FMRP targets were obtained on the basis of the proportion of rare synonymous variants observed in a recent large-scale survey of human genetic variation 30 . The observed and expected overlaps based on another recent study of FMRP targets 31 are given in Supplementary Table 5 . The significances of the overlaps were established using a two-tail binomial test. npg a r t I C l e S using the Human Brain Transcriptome database (HBT, http://hbatlas.org/) 16 . Based on postmortem transcriptional analysis of tissue samples from healthy individuals, the HBT database provides a comprehensive map of mRNA expression across multiple brain regions and developmental stages. We determined the average expression levels across developmental periods for the various gene sets that formed the implicated network, as well as for genes with truncating de novo SNVs. We used a Wilcoxon rank-sum test (P WT ) to estimate the significance of the expression difference between sets of biological samples and a permutation-based test (P PT ) to estimate the probability of observing a greater bias in random probe sets of equal size (Online Methods). The brain expression of network genes ( Fig. 2a) was significantly higher than the expression of SNV-containing genes that were not selected to the network (P WT < 10 −15 ; P PT < 10 −4 ). This result confirms that the implicated network is significantly enriched in brain-related genes. Notably, high brain expression of network genes is not simply a consequence of their length or connectivity in the phenotypic network; randomly selected human genes with equivalent length or network connectivity are expressed in the brain at significantly lower levels (P < 10 −4 ) across all developmental periods (Supplementary Fig. 2) . Expression of the network genes ( Fig. 2a) was, on average, highest during the early fetal to early mid-fetal periods (8-19 post-conception weeks), possibly as a result of higher activity of ASD-related genes in brain cells or changes in brain cellular composition. To quantify the prenatal expression bias, we calculated the difference between the expression during prenatal and postnatal developmental periods for every gene harboring de novo mutations. The prenatal bias was highly significant for network genes (bias 0.16, one-tail test, P WT < 10 −15 /P PT < 10 −4 ) and for genes with truncating SNVs (bias 0.18, P WT < 10 −15 /P PT < 10 −4 ). However, for ASD network genes with truncating de novo SNVs or de novo CNVs, embryonic expression (less than 8 post-conception weeks) was substantially lower as compared with that in later developmental periods (two-tail test, P WT = 6 × 10 −7 /P PT < 10 −4 and P WT = 10 −14 /P PT < 10 −4 , respectively; Fig. 2a ). This effect is apparent when comparing the average expression profiles for network genes with truncating (CNVs and truncating SNVs) and non-truncating mutations (Fig. 2b) . The bias against mutations in the embryonic period was absent for nonsynonymous de novo SNV genes not selected to the network (P WT = 0.4/P PT = 0.3) and for genes with de novo SNVs in siblings (P WT = 0.2/P PT = 0.2). The observed bias against de novo truncating SNVs and CNVs suggests that there is strong selection against harmful mutations during embryonic development, as these mutations lead to more severe developmental consequences than mutations typically associated with autism.
We also examined the temporal expression profiles for each of the four clusters forming the implicated network (Fig. 2c) . The cluster that was primarily associated with the postsynaptic density (Fig. 2c) had the highest overall expression in the brain. Both the PSD cluster and the cluster associated with various channel activities showed a distinct rise during early fetal development, consistent with the start of synaptogenesis at the early mid-fetal developmental stage. In contrast, the cluster associated with chromatin modification and regulation showed high embryonic and fetal expression, consistent with a developmental peak of neuronal proliferation and differentiation, and then gradually decreased to a postnatal plateau. Sustained expression of chromatin modification genes after neurodevelopmental stages may be attributed to their involvement in synaptic plasticity 35 . Finally, the cluster associated with neuronal signaling and cytoskeleton was relatively constant across all developmental stages. This is consistent with the important roles of signaling and structural genes across npg a r t I C l e S all developmental stages. Notably, there was substantial variability in the expression of the individual genes around the average cluster expression profiles (Supplementary Fig. 3 ). However, this variability is likely to be at least partially explained by different dosage requirements of individual genes. Normalized expression trajectories (Supplementary Fig. 3 ) revealed that the temporal profiles of individual genes were generally consistent with the average expression profiles of corresponding functional clusters.
A high male-to-female incidence ratio, estimated at more than 4:1 for high-functioning individuals, is one of the most consistent and notable findings in ASDs 36, 37 . Evidence suggests that this bias may be a result of a female protective effect that requires a higher threshold of genetic insults to trigger ASDs in females than in males 38 . We also observed that females in the SSC collection had a greater burden of truncating mutations than males (Fisher's exact one-tail test, P = 0.07), which is consistent with this hypothesis. This gender dimorphism was even stronger for the genes in the implicated network (30% of SNV mutations in females are truncating compared with 13% in males; Fisher's exact one-tail test, P = 0.03). Notably, the average brain expression was significantly higher for genes harboring truncating de novo mutations in females than in males (average log 2 expression for genes: females, 7.98; males, 7.40; one-tail test, P WT < 10 −15 /P PT = 2 × 10 −3 ; Fig. 2d ). These log-scale differences translate to absolute expression level differences of 50-100% across developmental stages in the average expression of genes harboring truncating SNVs in females and males. Thus, the expression data also suggest that relatively stronger genetic perturbations, that is, truncating mutations in genes with higher brain expression, are preferentially associated with ASDs in females. Notably, the observed expression patterns cannot be explained by normal expression differences between males and females. For genes with truncating SNV mutations in female probands the average brain expression levels in females and males were 8.02 and 7.95 (<5% difference), respectively; for genes with truncating SNVs in male probands the average brain expression levels in females and males were 7.42 and 7.39 (<3% difference), respectively. We also note that the relative difference in brain expression for genes harboring mutations in females versus males was larger for genes with truncating SNVs than for implicated network genes. This result is likely a consequence of the severe effect of truncating mutations on protein function, which makes the expression of corresponding genes an important factor in explaining the variability of ASD phenotypes across patients. To investigate whether ASD mutations preferentially affect specific brain regions, we analyzed spatial expression data available in the HBT database. For each brain region, we compared the average expression levels of network genes to the expression levels of genes with SNVs in unaffected siblings. Compared with controls, network genes showed significantly higher expression across all brain regions (Supplementary Table 7) , which is consistent with the wide spectrum of phenotypic abnormalities observed in ASDs. Furthermore, we investigated the Figure 3 Cell-type expression biases for network mutations and recurrent truncating mutations. Proband versus unaffected sibling expression biases were computed across 25 cell types of the CNS for implicated network genes (shown in red) and for 11 genes with recurrent truncating SNVs (blue). The biases were calculated using previously described Mus musculus expression data 17 . To quantify the expression biases, we calculated for each cell type the difference between the average log 2 expression of mouse orthologs for implicated human genes and the average log 2 expression of mouse ortholog for human genes with de novo SNVs in unaffected siblings. Cell types are ordered by the magnitude of the cell type expression bias for network genes (red). The significance of the expression biases was evaluated using the Wilcoxon rank-sum one-tail test and corrected for multiple hypothesis testing using the Benjamini-Hochberg procedure with a false discovery rate of 10%; significant cell types are shown in dark red and blue, and non-significant types are shown in light red and blue. In addition, the P values obtained from the two independent approaches, one based on network genes (red) and the other based on genes affected by recurrent truncating mutations (blue), were combined using Fisher's and Stouffer's meta-analysis methods.
The combined P values were corrected using the Bonferroni method, and the cell types passing the significance cutoff for both meta-analyses are indicated with an asterisk (*). All P values associated with the figure are presented in Supplementary Table 8 . The biases were calculated using human expression data obtained from the HBT database. To quantify the expression bias for each brain region, we calculated the difference between the average log 2 prenatal expression and the average log 2 postnatal expression, such that positive values in the table indicate higher expression levels in the prenatal periods. The significances of the expression biases were evaluated using the Wilcoxon rank-sum one-tail test and corrected using the Bonferroni procedure. Bias s.e.m. was calculated separately for each brain region. BG, basal ganglia. npg a r t I C l e S prenatal expression bias for network and truncating genes and compared these with the prenatal bias for genes with SNVs in siblings. We found that the prenatal bias was generally similar and statistically significant for all brain regions ( Table 3) . We note, however, that the amygdala, which is known to have a crucial role in processing emotional stimuli 39 , as well as cerebellum and striatum, showed a numerically, although not significantly, larger prenatal bias than other regions. Overall, however, the lack of regional specificity underscores the sharing of gene functions across brain areas. The human brain contains a variety of neuronal and non-neuronal cell types, and we sought to investigate possible biases of implicated genes toward specific cell types. To explore this question, we used an independent data set of cell-specific gene expression generated using translating ribosome affinity purification (TRAP) 17 ; the data set contains gene expression profiles for 25 distinct cell types from the mouse CNS. To assess cell-specific expression biases, we compared, for each cell type, the expression of mouse orthologs for the implicated network genes with the expression of orthologs for genes harboring mutations in unaffected siblings. This analysis revealed that multiple neuronal and non-neuronal cell types were likely affected by de novo ASD mutations in the network genes ( Fig. 3 and Supplementary  Table 8 ). The diversity of affected cells could be explained, at least partially, by shared usage of common signaling, structural and neural pathways across diverse cell types. Although multiple cell types were affected, particularly strong and significant expression biases for implicated network genes were observed in cortical neurons, especially cortical interneurons, pyramidal neurons and medium spiny neurons of the striatum (Fig. 3) . Notably, similar cell types were also independently implicated by considering expression biases for 11 genes with recurrent truncating de novo mutations (Fig. 3) . On the other hand, some other cell types, such as motor neurons and astroglial cells, were markedly less affected. Notably, deep layer cortical glutamatergic projection neurons were also identified recently as a point of spatio-temporal convergence in coexpression networks built around high confidence ASD genes 40 .
Functional properties of implicated genes and disease phenotypes
Because ASDs manifest substantial pathophysiological differences across probands, it is important to understand how functional properties of implicated genes and associated mutations affect phenotypic characteristics of the disease. To investigate the effect of truncating de novo mutations on IQ, we calculated, separately for CNVs and truncating SNVs, the average number of truncating mutations per individual across the IQ spectrum (Fig. 4a) . Notably, for highfunctioning ASD probands, the average number of truncating mutations (CNVs and truncating SNVs) decreased and became similar to the average number in unaffected siblings. The average number of truncating SNVs for probands with IQ less than 100 was about twofold higher than probands with IQ greater than or equal to 100 (0.17 for IQ < 100, 0.09 for IQ ≥ 100; Fisher's exact two-tail test, P = 0.02). In contrast, similar analyses for non-truncating mutations (synonymous and non-truncating SNVs) in probands showed that the average number of non-truncating mutations per individual was (Fig. 4b) , without a prominent decrease for high-functioning ASD probands (0.43 for IQ < 100, 0.46 for IQ ≥ 100; Fisher's exact two-tail test, P = 0.7). Relative to synonymous mutations, non-synonymous non-truncating were significantly enriched in probands with IQs above 70 compared with those below 70: 160 non-truncating and 72 synonymous mutations (2.2:1 ratio) were observed in probands with IQ ≤ 70, whereas 330 non-truncating and 110 synonymous mutations (3.3:1 ratio) in probands with IQ > 70 (Fisher's exact one-tail test, P = 0.04). Overall, these analyses suggest that truncating mutations are likely to play a less prominent role in high-functioning ASD cases. Another recent study 41 also demonstrated no excess of de novo loss-of-function mutations for high-functioning ASD probands.
Notably, there was a significant difference in IQs between probands with network genes affected by CNV deletions and duplications. The average IQs for probands with CNV deletions and duplications were 64.8 and 83.9, respectively (Wilcoxon rank-sum one-tail test, P = 6 × 10 −3 ). This result suggests that a decrease in gene dosage has a substantially stronger functional effect than an increase in dosage.
Given that genes exhibited diverse expression patterns, we asked whether the level of brain expression for affected genes is associated, on average, with different phenotypic outcomes. For this analysis, we considered the full-scale IQ and Autism Diagnostic InterviewRevised (ADIR) social interaction and repetitive behavior scores. The ADIR scores are based on structured interviews with proband parents and reflect patterns in reciprocal social interactions (ADIR-S) and repetitive/restrictive behaviors (ADIR-R) 42 . To explore the relationship between the average expression level of affected genes and corresponding phenotypes, we divided the ASD cases into low-and high-scoring phenotypic subsets relative to the corresponding median phenotype scores. We then calculated the average expression levels of implicated genes identified in each phenotype subset (Fig. 5) . This analysis revealed that affected genes associated with lower IQ scores or higher ADIR scores (both indicating more severe phenotypes) usually had significantly higher brain expression (network genes: one-tail test, P WT < 10 −15 /P PT = 0.01 for IQ, P WT < 10 −15 /P PT = 0.3 for ADIR-S, P WT < 10 −15 /P PT = 0.024 for ADIR-R; genes with truncating mutations: one-tail test, P WT < 10 −15 /P PT < 10 −4 for IQ, P WT < 10 −15 /P PT = 1.5 × 10 −3 for ADIR-S, P WT < 10 −15 /P PT = 0.08 for ADIR-R; Fig. 5 ).
DISCUSSION
Our results suggest that the pathophysiological heterogeneity of ASD is matched by the diversity of genetic and functional insults associated with the disorder. We found that affected genes had diverse developmental expression profiles and are therefore likely to be important in multiple stages of neurogenesis, neuron mobility, synaptogenesis and brain function. Although the implicated genes and processes are active across multiple cell types, some types, such as cortical interneurons, pyramidal neurons and medium spiny neuron of the striatum, seemed to be more strongly affected. Notably, layer 5 cortical pyramidal neurons often project to the striatum and layer 6 often project to the thalamus; the corresponding cortico-striatal-thalamic circuits are known to mediate diverse motor, emotional, cognitive and habit-forming behaviors that are often perturbed in ASD [43] [44] [45] [46] . Consequently, our unbiased genome-wide analysis implicates specific functional neural circuits that may mediate stereotypical and repetitive behaviors in ASD.
Although previous studies have primarily emphasized the role of truncating de novo mutations in ASD 3, 7, 8 , our analysis suggests that a substantial fraction of non-truncating de novo missense mutations observed in probands also contributes to the disorder. Notably, we found that functional mutations were preferentially observed in haploinsufficient genes, which confirms that dosage effects are important for the disease mechanisms. We found that functional characteristics of affected genes, such as brain expression levels, are likely to influence the observed phenotypic consequences of de novo ASD mutations. Stronger functional insults lead, on average, to more severe ASD phenotypes. Thus, the distinction between intellectual disability and autism may lie primarily in the degree of overall functional effect rather than specific genes and pathways affected in the two disorders.
Our analysis of brain expression provides further evidence for the hypothesis that stronger functional insults, such as perturbation of genes with substantially higher brain expression, are associated with female autistic phenotypes. Stronger functional perturbations in females were previously demonstrated through analyses of autism CNVs sizes 6, 47 and gene network properties 13 . Thus, multiple independent sources of evidence suggest a protective effect in females, although the mechanisms of this effect remain to be elucidated.
We also find, in agreement with recently published studies 41, 48 , that truncating mutations play a smaller role in high-functioning ASD cases. Because truncating mutations are usually associated with a loss of function, this result suggests that high-functioning autism phenotypes are less likely to be mediated by a loss of normal gene function in the brain. Functional gain and other types of genetic variations, such as non-truncating de novo mutations, common polymorphisms or mutations in non-coding regulatory regions, may be the primary contributors to high-functioning ASD cases.
Taken together, our results suggest that various functional properties of mutations and target genes may be useful in predicting ASD phenotypic severity. In the future, it will be important to investigate the extent to which individual ASD patients can be stratified on the basis of affected pathways, biological functions and cell types. Such patient stratification, now a common practice in cancer, may lead to individualized diagnostic and prognostic predictions and, ultimately, to targeted ASD therapies.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
ASd associated de novo variants. Variants were obtained from several recent studies of families in the SSC and included de novo CNVs 6 and de novo SNVs 3, 7, 8 . Overlapping CNVs were combined into a single event and CNVs larger than 5 Mb were ignored. When a gene affected by an SNV was also contained in a CNV event, the SNV gene was considered individually and the remaining genes in the CNV were considered as a separate event. Combining overlaps and removing duplicate genes resulted in 991 genes at 624 distinct genomic loci that were used as input in our analysis. 11 probands considered in our study had multiple SNV mutations; these probands were counted multiple times (once for each SNV) in various tests comparing mutations and corresponding functional properties. GERP scores used to assess the evolutionary severity of SNV mutations were obtained from the original studies 49 .
Phenotypic network and the neTBAg+ algorithm. The NETBAG+ algorithm relies on the previously described phenotypic network in which all pairs of human genes are assigned a score proportional to the likelihood ratio that genes contribute to the same genetic phenotype 12, 13 . This ratio was calculated using a naive Bayesian integration of various descriptors of protein function: shared GO annotations, shared pathways in Kyoto Encyclopedia of Genes and Genomes (KEGG), protein domains from the InterPro database, tissue expression from the TiGER database, direct protein-protein interactions, shared interaction partners in a number of databases (BIND, BioGRID, DIP, HPRD, InNetDB, IntAct, BiGG, MINT and MIPS), phylogenetic profiles and chromosomal co-clustering across genomes 50 . The likelihood network was constructed using a carefully curated set of human genes compiled by a previous study 51 that contains 476 human genes associated with 132 different genetic phenotypes.
The 991 genes affected by de novo mutations were mapped to the corresponding nodes of the phenotypic network. A greedy search algorithm was then used to find strongly interconnected networks among the input genes; starting from each input gene, the greedy algorithm consecutively adds the genes most strongly connected to the growing network. Networks are scored based on a weighted sum of all pairwise likelihood scores between the network genes 12, 13 . Each CNV event was constrained to contribute at most one gene to the network. Small networks with five or fewer genes were ignored during the network searches.
Network significance was determined by applying the same greedy search algorithm to 5,000 random gene sets and comparing the score of the network obtained using real input data to the distribution of network scores obtained using random gene sets. The random gene sets used in the calculations were chosen to match the input genes in terms of network connectivity (based on the average of the top five edge scores) and protein lengths to ensure that network significance was not driven by highly connected or long genes; genes affected by de novo ASD mutations were allowed to participate in the randomization sets. The final network P value reflects the probability of finding a higher scoring network using random gene sets while also accounting for multiple hypothesis testing as a result of various network sizes 12, 13 . The final network of 159 genes was selected as the largest network before a considerable decrease in network significance.
FmRP and PSd enrichment among implicated gene sets. Following a previously described approach 3 and other similar studies, we estimated the enrichments using the overlap between FMRP targets 27, 31 or PSD genes 32 and a set of rare synonymous mutations from a large exome sequencing study; we used for this purpose the NHLBI ESP exome-sequencing study 30 . Using the exomesequencing data of about 6,500 individuals, we calculated the fractions of all rare synonymous mutations, that is, synonymous mutations observed in the study only once, that affect FMRP target genes and genes associated with PSD. NHLBI ESP variant data was downloaded from http://evs.gs.washington.edu and unique entries were determined using the variant chromosomal position and allele. The calculated fractions represent the background (expected) probabilities for a random SNV mutation to occur in FMRP and PSD genes. We then compared the expected and the observed fractions of SNVs events in various ASD disease gene sets using a two-tail binomial test (Table 2 and Supplementary Table 5 ). We also confirmed the FMRP enrichment results by comparing the overlap of FMRP target genes with various ASD gene sets to the overlap of FMRP target genes with random sets of human genes matched by protein length and network connectivity to the genes affected by ASD mutations (Supplementary Table 6 ).
Hierarchical clustering of the implicated network. We used the average linkage hierarchical clustering to divide the implicated network into functional clusters (Supplementary Fig. 1 ). The inverses of the phenotypic network likelihood scores were used as the clustering metric.
Spatial and temporal analysis of human brain expression. Expression data across developmental stages and brain regions was obtained from the Human Brain Transcriptome database (GEO accession ID, GSE25219) 16 ; the HBT data represents quantile-normalized and log 2 -transformed expressions values from the post-mortem brain samples from healthy individuals.
To quantify the expression biases for each brain region, we calculated the difference between the average log 2 expression of implicated genes and the average log 2 expression of genes harboring SNVs in siblings. The prenatal expression bias for each brain region was quantified by calculating the difference between the average log 2 of prenatal expression (embryonic to late fetal stages) and the average log 2 postnatal expression (early infancy to late adulthood stages). The significance of regional and prenatal biases was evaluated using the Wilcoxon rank-sum test with a Bonferroni correction to account for multiple hypothesis testing.
Complementary to the Wilcoxon rank-sum test (P WT ), we also estimated the significance of various expression differences using a method based on randomly generated expression probe sets (Supplementary Table 9 ). The permutation test P values (P PT ) obtained with the random trials reflect the probability to obtain a bias greater or equal to the bias in the original data. The numbers of probe sets sampled in each of 10,000 random trials were equal to the numbers of probes sets in corresponding original gene sets. Analogous to the procedure used to process the original HBT data, we computed transcript-level expression by taking the median expression value of probe sets; expression biases were then calculated by taking the difference between the corresponding expression averages.
cell type-specific expression analysis. To evaluate expression bias of the implicated genes toward specific cell types, we considered mouse expression data obtained previously 17 using ribosome affinity purification (GEO accession ID GSE13379). The considered data set contains expression information for 25 different cell types from the Mus musculus CNS. To connect the mouse expression data and the human genetic data, we used the list of human-mouse orthologs provided by Affymetrix for the Mouse Genome 430 Array. The expression biases in probands compared to siblings were quantified for each cell type by calculating the difference between the average log 2 expression of mouse orthologs for implicated human genes and the average log 2 expression of mouse ortholog for human genes with de novo SNVs in unaffected siblings. We evaluated significances of the expression biases using the Wilcoxon rank-sum one-tail test and corrected for multiple hypothesis testing using the Benjamini-Hochberg procedure. P values obtained from the two independent approaches, one based on network genes and the other based on genes affected by recurrent truncating mutations, were combined using Fisher's and Stouffer's meta-analysis methods. The combined P values were corrected using the Bonferroni method.
A Supplementary methods checklist is available. 
